Tags

Type your tag names separated by a space and hit enter

Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults.
Sci Rep. 2019 08 21; 9(1):12210.SR

Abstract

The therapeutic effects of B. coagulans Unique IS2 have been well established in children with irritable bowel syndrome (IBS), but its efficacy in adults remain under reported. Thus, in this study the efficacy of B. coagulans Unique IS2 in the management of IBS symptoms in adults was investigated. Patients (n = 153) fulfilling Rome III criteria were provided placebo capsules for a 2 weeks run-in period. Only patients satisfying compliance criteria (n = 136) were randomized (double blind) to receive either B. coagulans Unique IS2 (2 billion CFU) or placebo capsules daily for 8 weeks. Reduction of abdominal discomfort/pain intensity and increase in complete spontaneous bowel movements were analyzed as primary end points. Other clinical symptoms of IBS and serum cytokines were also evaluated. B. coagulans Unique IS2 showed significant improvement in primary and secondary endpoints, as compared to placebo. Haematology of both the arms remained normal. No significant changes in pro- (IL-6, IL-12, TNF-α, INF- γ) and anti-inflammatory cytokine (IL-10) levels were detected at the end of B. coagulans treatment (8 weeks) as compared to placebo. B. coagulans was well tolerated with no severe adverse events to report. Overall, the results demonstrate that B. coagulans Unique IS2 is efficacious in the management of IBS symptoms in adults (18-60 years).

Authors+Show Affiliations

Centre for Research & Development, Unique Biotech Ltd., Plot No. 2, Phase-II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India. sudha@uniquebiotech.com.Centre for Research & Development, Unique Biotech Ltd., Plot No. 2, Phase-II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India.Centre for Research & Development, Unique Biotech Ltd., Plot No. 2, Phase-II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India.Life Veda Treatment and Research Centre, Worli, Mumbai, 400030, India.Nanal Clinic, Anand Bhuvan, Gore wadi, Mahim (W), Mumbai, 400016, India.

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31434935

Citation

Madempudi, Ratna Sudha, et al. "Randomized Clinical Trial: the Effect of Probiotic Bacillus Coagulans Unique IS2 Vs. Placebo On the Symptoms Management of Irritable Bowel Syndrome in Adults." Scientific Reports, vol. 9, no. 1, 2019, p. 12210.
Madempudi RS, Ahire JJ, Neelamraju J, et al. Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Sci Rep. 2019;9(1):12210.
Madempudi, R. S., Ahire, J. J., Neelamraju, J., Tripathi, A., & Nanal, S. (2019). Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Scientific Reports, 9(1), 12210. https://doi.org/10.1038/s41598-019-48554-x
Madempudi RS, et al. Randomized Clinical Trial: the Effect of Probiotic Bacillus Coagulans Unique IS2 Vs. Placebo On the Symptoms Management of Irritable Bowel Syndrome in Adults. Sci Rep. 2019 08 21;9(1):12210. PubMed PMID: 31434935.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. AU - Madempudi,Ratna Sudha, AU - Ahire,Jayesh J, AU - Neelamraju,Jayanthi, AU - Tripathi,Anirudh, AU - Nanal,Satyavrat, Y1 - 2019/08/21/ PY - 2018/10/25/received PY - 2019/08/05/accepted PY - 2019/8/23/entrez PY - 2019/8/23/pubmed PY - 2020/10/21/medline SP - 12210 EP - 12210 JF - Scientific reports JO - Sci Rep VL - 9 IS - 1 N2 - The therapeutic effects of B. coagulans Unique IS2 have been well established in children with irritable bowel syndrome (IBS), but its efficacy in adults remain under reported. Thus, in this study the efficacy of B. coagulans Unique IS2 in the management of IBS symptoms in adults was investigated. Patients (n = 153) fulfilling Rome III criteria were provided placebo capsules for a 2 weeks run-in period. Only patients satisfying compliance criteria (n = 136) were randomized (double blind) to receive either B. coagulans Unique IS2 (2 billion CFU) or placebo capsules daily for 8 weeks. Reduction of abdominal discomfort/pain intensity and increase in complete spontaneous bowel movements were analyzed as primary end points. Other clinical symptoms of IBS and serum cytokines were also evaluated. B. coagulans Unique IS2 showed significant improvement in primary and secondary endpoints, as compared to placebo. Haematology of both the arms remained normal. No significant changes in pro- (IL-6, IL-12, TNF-α, INF- γ) and anti-inflammatory cytokine (IL-10) levels were detected at the end of B. coagulans treatment (8 weeks) as compared to placebo. B. coagulans was well tolerated with no severe adverse events to report. Overall, the results demonstrate that B. coagulans Unique IS2 is efficacious in the management of IBS symptoms in adults (18-60 years). SN - 2045-2322 UR - https://www.unboundmedicine.com/medline/citation/31434935/Randomized_clinical_trial:_the_effect_of_probiotic_Bacillus_coagulans_Unique_IS2_vs__placebo_on_the_symptoms_management_of_irritable_bowel_syndrome_in_adults_ L2 - https://doi.org/10.1038/s41598-019-48554-x DB - PRIME DP - Unbound Medicine ER -